444-93-9

Basic information

• Product Name: N-(2-trifluoromethylphenyl)-2-oxyiminoacetamide
• Synonyms: N-(2-trifluoromethylphenyl)-2-oxyiminoacetamide
• CAS NO: 444-93-9
• Molecular Formula: C₉H₇F₃N₂O₂
• Molecular Weight: 232.1592896
• Mol File: 444-93-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(2-trifluoromethylphenyl)-2-oxyiminoacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-trifluoromethylphenyl)-2-oxyiminoacetamide(444-93-9)
• EPA Substance Registry System: N-(2-trifluoromethylphenyl)-2-oxyiminoacetamide(444-93-9)

Safety Data

• Hazardous Substances Data: 444-93-9(Hazardous Substances Data)

Usage

General Description

N-(2-trifluoromethylphenyl)-2-oxyiminoacetamide is an organic compound with the molecular formula C10H7F3N2O2. It is a white solid that is used in the pharmaceutical industry as an intermediate in the synthesis of various drugs. The compound contains a combination of nitrogen, oxygen, carbon, and hydrogen atoms, and its structure includes a trifluoromethylphenyl group and an oxyimine functional group. Its properties make it a potentially useful building block for the production of pharmaceuticals or other organic compounds. However, it is important to handle this chemical with caution due to its potential reactivity and toxicity.

Upstream product

• 302-17-0 chloral hydrate 
• 88-17-5 2-(trifluoromethyl)benzenamine 
• 3792-04-9 2-chloro-N-[2-(trifluoromethyl)phenyl]acetamide 
• 75-87-6 chloral 

Downstream Products

• 391-12-8 7-trifluoromethylisatin 
• 74396-78-4 7-Trifluoromethylisatin β-oxime 
• 2251-78-7 4-(trifluoromethyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one 
• 1075753-27-3 2-chloro-4-(trifluoromethyl)-1H-benzo[d]imidazole 
• 313-12-2 2-amino-3-(trifluoromethyl)benzoic acid 
• 50419-85-7 2-amino-5-bromo-3-(trifluoromethyl)benzoic acid 

Relevant articles and documents

Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof

The invention discloses a benzenesulfonamide compound represented by a general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method and application thereof. Compared with the prior art, the benzenesulfonamide compound disclosed by the invention can be used as an isocitrate dehydrogenase 2 (IDH2) mutant inhibitor. According to the invention, pharmacological experiment results show that the compound disclosed by the invention has an obvious inhibiting effect on the activity of an IDH2 mutant (mIDH2), can effectively inhibit the process of catalyzing alpha-ketoglutaricacid to generate 2-hydroxyglutaric acid by mIDH2, and can be used for preventing and/or treating various related diseases including cancers and the like caused by IDH2 mutation.

Design, synthesis and insecticidal activities of novel anthranilic diamides containing fluorinated groups as potential ryanodine receptors activitors

In order to search for novel potent and environmentally benign insecticides, a series of anthranilic diamides containing various fluorinated groups were designed and synthesized. Their structures were confirmed by 1H NMR, 13C NMR, s

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.